Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) is one of the best up and coming penny stocks to buy. On February 4, Regentis Biomaterials appointed Ori Gon as Chief Financial Officer and Chief Business Officer to lead the company’s financial strategy and commercial development. Gon joined the regenerative medicine firm as its lead product, GelrinC, nears commercial launch in Europe and progresses through a pivotal Phase III FDA trial in the US.

With over 15 years of experience in medtech and capital markets, including senior roles at Tactile Mobility and ReWalk Robotics, Gon is expected to play a key role in establishing strategic partnerships and securing sustainable revenue growth. Executive Chairman Dr. Ehud Geller emphasized that Gon’s appointment strengthens the leadership team during the company’s transition from a development-stage entity to a commercial enterprise.

The company’s flagship product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed for the repair of focal knee cartilage defects. It has already received CE Mark approval in Europe and is currently at the midpoint of its US clinical trial enrollment. The treatment is marketed as a cost-effective, 10-minute procedure that allows for faster recovery and provides sustained pain relief for patients.

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) is a regenerative medicine company that develops tissue repair solutions in the US.

While we acknowledge the potential of RGNT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.